# US 2002/0164717 A1 · Nucleic acids encoding plasminogen fragments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0164717 A1
- Document ID: US20020164717A1
- Status: Published application
- Kind: A1
- Application number: 09/335,325
- Filed: 1999-06-17
- Published: 2002-11-07
- Earliest claimed: 1996-03-08
- Assignees: Children's Medical Center Corporation
- Inventors: M. JUDAH FOLKMAN; MICHAEL S. O'REILLY; YIHAI CAO
- Web page: https://patentgrep.com/patent/US20020164717A1

## CPC

- C12N 9/6435: {Plasmin (3.4.21.7), i.e. fibrinolysin}
- C12Y 304/21007: Plasmin (3.4.21.7), i.e. fibrinolysin
- G01N 33/575: for cancer
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Fragments of an endothelial cell proliferation inhibitor and method of use therefor are provided. The endothelial proliferation inhibitor is a protein derived from plasminogen, or more specifically is an angiostatin fragment. The angiostatin fragments generally correspond to kringle structures occurring within the endothelial cell proliferation inhibitor. The endothelial cell inhibiting activity of these fragments provides a means for inhibiting angiogenesis of tumors and for treating angiogenic-mediated disease.

## Claims

### Claim 1

A method of inhibiting endothelial cell proliferation comprising administering to an endothelial cell a proliferation inhibiting amount of an angiostatin fragment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the angiostatin fragment has an ED50 of less than about 500 nM.

### Claim 3 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is derived from murine plasminogen, human plasminogen, Rhesus plasminogen, porcine plasminogen or bovine plasminogen.

### Claim 4 (depends on 1)

The method of claim 1, wherein the angiostatin fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ.ID NO:14; SEQID NO:15; SEQID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ IID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:41 and SEQ ID NO:42 or a combination thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is a kringle 1 protein.

### Claim 6 (depends on 5)

The method of claim 5, wherein the kringle I protein has an ED50 of less than about 350 nM.

### Claim 7 (depends on 5)

The method of claim 5, wherein the kringle 1 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10 and SEQ ID NO: 11.

### Claim 8 (depends on 5)

The method of claim 5, wherein the kringle 1 protein comprises an amino acid sequence of SEQ ID NO:8.

### Claim 9 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is a kringle 2 protein.

### Claim 10 (depends on 9)

The method of claim 9, wherein the kringle 2 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15 and SEQ ID NO:16.

### Claim 11 (depends on 9)

The method of claim 9, wherein the kringle 2 protein comprises an amino acid sequence of SEQ ID NO:13.

### Claim 12 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is a kringle 3 protein.

### Claim 13 (depends on 12)

The method of claim 12, wherein the kringle 3 protein has an ED5O of less than about 475 nM.

### Claim 14 (depends on 12)

The method of claim 12, wherein the kringle 3 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20 and SEQ ID NO:21.

### Claim 15 (depends on 12)

The method of claim 12, wherein the kringle 3 protein comprises an amino acid sequence of SEQ ID NO: 18.

### Claim 16 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is a kringle 2-3 protein.

### Claim 17 (depends on 16)

The method of claim 16, wherein the kringle 2-3 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27 and SEQ ID NO:28.

### Claim 18 (depends on 16)

The method of claim 16, wherein the kringle 2-3 protein comprises an amino acid sequence of SEQ ID NO:25.

### Claim 19 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is a kringle 1-3 protein.

### Claim 20 (depends on 19)

The method of claim 19, wherein the kringle 1-3 protein has and ED50 of less than about 100 nM.

### Claim 21 (depends on 19)

The method of claim 19, wherein the kringle 1-3 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32 and SEQ ID NO:33.

### Claim 22 (depends on 16)

The method of claim 16, wherein the kringle 1-3 protein comprises an amino acid sequence of SEQ ID NO:30.

### Claim 23 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is a kringle 1-2 protein.

### Claim 24 (depends on 23)

The method of claim 23, wherein the kringle 1-2 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37 and SEQ ID NO:38.

### Claim 25 (depends on 23)

The method of claim 23, wherein the kringle 1-2 protein comprises an amino acid sequence of SEQ ID NO:35.

### Claim 26 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is a kringle 1-4 protein.

### Claim 27 (depends on 26)

The method of claim 26, wherein the kringle 1-4 protein has an ED50 of less than about 150 nM.

### Claim 28 (depends on 26)

The method of claim 26, wherein the kringle 1-4 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:39 and SEQ ID NO:40.

### Claim 29 (depends on 1)

The method of claim 1, wherein the angiostatin fragment is a kringle 1-4BKLS protein.

### Claim 30 (depends on 29)

The method of claim 29, wherein the kringle 1-4BKLS protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:41 and SEQ ID NO:42.

### Claim 31 (depends on 29)

The method of claim 29, wherein the kringle 1-4BKLS protein comprises an amino acid sequence of SEQ ID NO:42.

### Claim 32 (depends on 1)

The method of claim 1 wherein the administering step comprises administering a combination of two or more angiostatin fragments.

### Claim 33 (depends on 32)

The method of claim 32, wherein the angiostatin fragment is derived from murine plasminogen, human plasminogen, Rhesus plasminogen, porcine plasminogen or bovine plasminogen.

### Claim 34 (depends on 32)

The method of claim 32, wherein the combination of angiostatin fragments comprises a kringle I protein and a kringle 2 protein.

### Claim 35 (depends on 34)

The method of claim 34, wherein the kringle 1 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10 and SEQ ID NO:11, and the kringle 2 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15 and SEQ ID NO:16.

### Claim 36 (depends on 34)

The method of claim 34, wherein the kringle I protein comprises an amino acid sequence of SEQ ID NO:8 and the kringle 2 protein comprises an amino acid sequence of SEQ ID NO:13.

### Claim 37 (depends on 32)

The method of claim 32, wherein the combination of angiostatin fragments comprises a kringle I protein and a kringle 2-3 protein.

### Claim 38 (depends on 37)

The method of claim 37, wherein the kringle 1 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10 and SEQ ID NO:11, and the kringle 2-3 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27 and SEQ ID NO:28.

### Claim 39 (depends on 37)

The method of claim 37, wherein the kringle 1 protein comprises an amino acid sequence of SEQ ID NO:8 and the kringle 2-3 protein comprises an amino acid sequence of SEQ ID NO:25.

### Claim 40 (depends on 32)

The method of claim 32, wherein the combination of angiostatin fragments comprises a kringle 1 protein, a kringle 2 protein and a kringle 3 protein.

### Claim 41 (depends on 40)

The method of claim 40, wherein the kringle 1 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10 and SEQ ID NO:11, the kringle 2 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO: 14; SEQ ID NO:15 and SEQ ID NO:16, and the kringle 3 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20 and SEQ ID NO:21.

### Claim 42 (depends on 40)

The method of claim 40, wherein the kringle 1 protein comprises an amino acid sequence of SEQ ID NO:8, the kringle 2 protein comprises an amino acid sequence of SEQ ID NO: 13 and the kringle 3 protein comprises an amino acid sequence of SEQ ID NO:18.

### Claim 43 (depends on 32)

The method of claim 32, wherein the combination of angiostatin fragments comprises a kringle 2 protein and a kringle 3 protein.

### Claim 44 (depends on 43)

The method of claim 43, wherein the kringle 2 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15 and SEQ ID NO:16, and the kringle 3 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20 and SEQ ID NO:21.

### Claim 45 (depends on 43)

The method of claim 43, wherein the kringle 2 protein comprises an amino acid sequence of SEQ ID NO:13 and the kringle 3 protein comprises an amino acid sequence of SEQ ID NO:18.

### Claim 46

A method of treating a mammal with an angiogenic-mediated disease comprising administering to the mammal a treatment effective amount of an angiostatin fragment.

### Claim 47 (depends on 46)

The method of claim 46, wherein the mammal is a human.

### Claim 48 (depends on 46)

The method of claim 46, wherein the angiogenic mediated disease is selected from the group consisting of cancer, arthritis, macular degeneration and diabetic retinopathy.

### Claim 49 (depends on 46)

The method of claim 46, wherein the angiostatin fragment is selected from the group consisting of a kringle 1 protein, kringle 2 protein, kringle 3 protein, kringle 2-3 protein, kringle 1-3 protein, kringle 1-2 protein, kringle 1-4 protein and kringle 1-4BKLS protein, or a combination thereof.

### Claim 50 (depends on 46)

The method of claim 46, wherein the angiostatin fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:41 and SEQ ID NO:42, or a combination thereof.

### Claim 51 (depends on 46)

The method of claim 46, wherein the angiostatin fragment has an endothelial cell ED50 of less than about 500 nM.

### Claim 52

A therapeutic composition for inhibiting endothelial cell proliferation comprising a substantially isolated angiostatin fragment and a pharmaceutically acceptable excipient.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the angiostatin fragment is derived from murine plasminogen, human plasminogen, Rhesus plasminogen, porcine plasminogen or bovine plasminogen.

### Claim 54 (depends on 52)

The composition of claim 52, wherein the angiostatin fragment is selected from the group consisting of a kringle 1 protein, kringle 2 protein, kringle 3 protein, kringle 2-3 protein, kringle 1-3 protein, kringle 1-2 protein, kringle 1-4 protein and kringle 1-4BKLS, or a combination thereof.

### Claim 55 (depends on 52)

The composition of claim 52, wherein the angiostatin fragment comprises a portion of an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ D NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:41 and SEQ ID NO:42, or a combination thereof.

### Claim 56

A composition comprising an isolated DNA sequence that codes for an angiostatin fragment having an endothelial cell proliferation inhibiting activity.

### Claim 57 (depends on 56)

The composition of claim 56, wherein the angiostatin fragment is selected from the group consisting of a kringle 1 protein, kringle 2 protein, kringle 3 protein, kringle 2-3 protein, kringle 1-3 protein, kringle 1-2 protein, kringle 1-4 protein and kringle 1-4BKLS, or a combination thereof.

### Claim 58 (depends on 56)

The composition of claim 56, wherein the DNA sequence codes for an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:41 and SEQ ID NO:42, or a combination thereof.

### Claim 59 (depends on 56)

The composition of claim 56, further comprising a vector associated with the DNA sequence encoding angiostatin fragment, wherein the vector is capable of expressing angiostatin fragment when present in a cell.

### Claim 60 (depends on 59)

The composition of claim 59, further comprising a cell containing said vector.

### Claim 61

A method of expressing angiostatin fragment having an endothelial cell proliferation inhibiting activity comprising transfecting in a mammalian cell a vector, wherein the vector contains a DNA sequence encoding said angiostatin fragment, and wherein the vector is capable of expressing angiostatin fragment when present in the cell.

### Claim 62 (depends on 61)

The method of claim 61, wherein the angiostatin fragment is selected from the group consisting of a kringle 1 protein, kringle 2 protein, kringle 3 protein, kringle 2-3 protein, kringle 1-3 protein, kringle 1-2 protein, kringle 1-4 protein and kringle 1-4BKLS, or a combination thereof.

### Claim 63 (depends on 61)

The method of claim 61, wherein the DNA sequence codes for angiostatin fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO: 10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:41 and SEQ ID NO: 42, or a combination thereof.
